Bruce Psaty is a general internist and cardiovascular disease epidemiologist with interests and expertise in pharmaco-epidemiology, pharmacogenetics, and drug safety. Also a professor of medicine, epidemiology, and health services at the University of Washington (UW), he co-directs the UW’s Cardiovascular Health Research Unit.
Dr. Psaty’s work includes population-based case-control studies of myocardial infarction, stroke, atrial fibrillation, and venous thromboembolism conducted at Group Health Cooperative. His primary research interests include risk factors such as high blood pressure, dyslipidemia, and diabetes and the drugs used to treat these conditions; new or emerging risk factors for heart disease and stroke; genetics, genomics, and pharmacogenetics; and genetic risk factors for a variety of conditions.
His several current NIH-funded projects focus on interactions between medications and genes; they represent efforts to translate findings from the Human Genome Project into clinical practice and, thus, improve the safety and efficacy of commonly used medications. He is a founding member of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (CHARGE), which conducts genome-wide association studies in collaborating cohorts, including the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis, funded by the National Heart, Lung, and Blood Institute. He also teaches and mentors students, fellows, and junior faculty in medicine and epidemiology.
A national leader in encouraging better postmarket surveillance of approved medications, Dr. Psaty is a member of the U.S. Food and Drug Administration (FDA)’s Science Board, a committee that advises the commisioner and chief scientist. He previously served on two Institute of Medicine (IOM) panels charged with reviewing the FDA, most recently the ethical and scientific issues in studying the safety of approved drugs. Dr. Psaty is also a member of the National Heart, Lung, and Blood Institute’s Advisory Council. In 2013, he was elected to the IOM and designated a distinguished scientist by the American Heart Association.
Dr. Psaty maintains a small but long-standing primary care practice in the Adult Medicine Clinic at Harborview Medical Center.
Walford GA, Gustafsson S, Rybin D, Stancakova A, Chen H, Liu CT, Hong J, Jensen RA, Rice K, Morris AP, Magi R, Tonjes A, Prokopenko I, Kleber ME, Delgado G, Silbernagel G, Jackson AU, Appel EV, Grarup N, Lewis JP, Montasser ME, Landenvall C, Staiger H, Luan J, Frayling TM, Weedon MN, Xie W, Morcillo S, Martínez-Larrad MT, Biggs ML, Ida Chen YD, Corbaton-Anchuelo A, Færch K, Zumaquero JM, Goodarzi MO, Kizer J, Koistinen HA, Leong A, Lind L, Lindgren C, Machicao F, Manning AK, Martín-Núñez GM, Rojo-Martínez G, Rotter JI, Siscovick DS, Zmuda JM, Zhang Z, Serrano-Rios M, Smith U, Soriguer F, Hansen T, Jørgensen TJ, Linnenberg A, Pedersen O, Walker M, Langenberg C, Scott RA, Wareham NJ, Fritsche A, Häring HU, Stefan N, Groop L, O'Connell JR, Boehnke M, Bergman RN, Collins FS, Mohlke KL, Tuomilehto J, März W, Kovacs P, Stumvoll M, Psaty BM, Kuusisto J, Laakso M, Meigs JB, Dupuis J, Ingelsson E, Florez JC. Genome-wide association study of the modified Stumvoll Insulin Sensitivity Index identifies BCL2 and FAM19A2 as novel insulin sensitivity loci. Diabetes. 2016 Jul 14. pii: db160199. [Epub ahead of print]. PubMed
Gruber S, Chakravarty A, Heckbert SR, Levenson M, Martin D, Nelson JC, Psaty BM, Pinheiro S, Reich CG, Toh S, Walker AM. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. Pharmacoepidemiol Drug Saf. 2016 Jul 14. doi: 10.1002/pds.4065. [Epub ahead of print]. PubMed
Chami N, Chen MH, Slater AJ, Eicher JD, Evangelou E, Tajuddin SM, Love-Gregory L, Kacprowski T, Schick UM, Nomura A, Giri A, Lessard S, Brody JA, Schurmann C, Pankratz N, Yanek LR, Manichaikul A, Pazoki R, Mihailov E, Hill WD, Raffield LM, Burt A, Bartz TM, Becker DM, Becker LC, Boerwinkle E, Bork-Jensen J, Bottinger EP, O'Donoghue ML, Crosslin DR, de Denus S, Dubé MP, Elliott P, Engström G, Evans MK, Floyd JS, Fornage M, Gao H, Greinacher A, Gudnason V, Hansen T, Harris TB, Hayward C, Hernesniemi J, Highland HM, Hirschhorn JN, Hofman A, Irvin MR, Kähönen M, Lange E, Launer LJ, Lehtimäki T, Li J, Liewald DC, Linneberg A, Liu Y, Lu Y, Lyytikäinen LP, Mägi R, Mathias RA, Melander O, Metspalu A, Mononen N, Nalls MA, Nickerson DA, Nikus K, O'Donnell CJ, Orho-Melander M, Pedersen O, Petersmann A, Polfus L, Psaty BM, Raitakari OT, Raitoharju E, Richard M, Rice KM, Rivadeneira F, Rotter JI, Schmidt F, Smith AV, Starr JM, Taylor KD, Teumer A, Thuesen BH, Torstenson ES, Tracy RP, Tzoulaki I, Zakai NA, Vacchi-Suzzi C, van Duijn CM, van Rooij FJ, Cushman M, Deary IJ, Velez Edwards DR, Vergnaud AC, Wallentin L, Waterworth DM, White HD, Wilson JG, Zonderman AB, Kathiresan S, Grarup N, Esko T, Loos RJ, Lange LA, Faraday N, Abumrad NA, Edwards TL, Ganesh SK, Auer PL, Johnson AD, Reiner AP, Lettre G. Exome genotyping identifies pleiotropic variants associated with red blood cell traits. Am J Hum Genet. 2016;99(1):8-21. doi: 10.1016/j.ajhg.2016.05.007. Epub 2016 Jun 23. PubMed
van Loon J, Dehghan A, Weihong T, Trompet S, McArdle WL, Asselbergs FF, Chen MH, Lopez LM, Huffman JE, Leebeek FW, Basu S, Stott DJ, Rumley A, Gansevoort RT, Davies G, Wilson JJ, Witteman JC, Cao X, de Craen AJ, Bakker SJ, Psaty BM, Starr JM, Hofman A, Wouter Jukema J, Deary IJ, Hayward C, van der Harst P, Lowe GD, Folsom AR, Strachan DP, Smith N, de Maat MP, O'Donnell C. Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet. 2015 Oct 21. doi: 10.1038/ejhg.2015.222. [Epub ahead of print].
Dr. Sascha Dublin describes a Group Health-UW finding that benzodiazepines probably don’t cause dementia. But she cautions that they’re still bad for you.
Read it in Healthy Findings.
New York Times, Feb 13, 2012